
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics, a clinical-stage oncology company, is developing innovative therapies targeting oncogenic mutations, with promising initial Phase 2 results for its lead drug BDTX-1535 showing a 36% objective response rate (ORR) among evaluable patients in a relapsed/refractory non-small cell lung cancer (NSCLC) setting. The encouraging data, particularly the 42% ORR when focusing on patients with on-target resistance mutations, highlights the potential of BDTX-1535 to address unmet medical needs in patients with non-classical EGFR mutations, where current treatments are inadequate. Moreover, a significant portion of patients (74%) remained on treatment at the time of data cut, suggesting the potential for sustained efficacy as the company prepares for future data updates in 2025 that could further validate its market opportunities.
Bears say
Black Diamond Therapeutics Inc faces significant risks regarding its drug pipeline, particularly concerning the potential for negative efficacy data and an inadequate safety profile for its lead candidate, BDTX-1535, which could impact the overall therapeutic development. Adjustments to expense assumptions and commercialization timelines have led to a decrease in the projected valuation, reflecting an anticipated full-year net loss of $1.32 for 2025, indicating ongoing financial challenges. Additionally, the possibility of long-term dilution poses further concerns, potentially affecting shareholder value and the company's financial stability.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares